EquitiesMedium impact
Viking Therapeutics: Still Cheap, But Watch Double Top (NASDAQ:VKTX)
seekingalpha.com·gestern·Global·1 min read
Source: seekingalpha.com
Viking Therapeutics remains attractive, advancing its GLP-1 weight-loss pipeline, with Phase 3 trials progressing.
Read more on VKTX stock here.
If you'd like to learn more about how to best position yourself in under valued stocks mispriced by the market to start Q3, consider joining Out Fox The Street...
Related news
Equities
Cathie Wood buys $22.8 million of surging tech stock
finance.yahoo.com
Equities
The AI Trade Is Rotating From Chips to Infrastructure. 2 Stocks Riding the Shift.
finance.yahoo.com
Equities
NVIDA Vs. Tesla: Tesla Jumps as It Finally Fulfills Decade-Old Promise So Buy Nvidia Instead
finance.yahoo.com
Equities
SBI’s OFS size in SBI MF IPO reduces by 2.88 crore equity shares following secondary share sale
thehindubusinessline.com
Equities
Bank OZK: The 7.2% Yielding Preferred Shares Are Still Interesting (NASDAQ:OZK)
seekingalpha.com
Equities
Wendy’s Vs. McDonald’s: Buy Wendy’s to Ride the ‘Project Fresh’ Short-Squeeze Momentum and Avoid McDonald’s
finance.yahoo.com